WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 18.08.2018 at 9:00 AM CEST
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017062451) GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/062451 International Application No.: PCT/US2016/055492
Publication Date: 13.04.2017 International Filing Date: 05.10.2016
IPC:
A61K 39/00 (2006.01) ,A61K 35/17 (2015.01) ,C12N 5/0783 (2010.01) ,C12N 15/113 (2010.01)
Applicants: PRECISION BIOSCIENCES, INC.[US/US]; 302 East Pettigrew Street Dibrell Building, Suite A-100 Durham, NC 27701, US
Inventors: JANTZ, Derek; US
SMITH, James, Jefferson; US
NICHOLSON, Michael, G.; US
MACLEOD, Daniel, T.; US
ANTONY, Jeyaraj; US
BARTSEVICH, Victor; US
Agent: TWOMEY, Michael, J.; US
Priority Data:
62/237,39405.10.2015US
62/297,42619.02.2016US
Title (EN) GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
(FR) CELLULES GÉNÉTIQUEMENT MODIFIÉES COMPRENANT UN GÈNE MODIFIÉ DE RÉGION CONSTANTE ALPHA DE RÉCEPTEUR DE LYMPHOCYTES T HUMAINS
Abstract: front page image
(EN) Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
(FR) La présente invention concerne une cellule génétiquement modifiée comprenant dans son génome un gène modifié de région constante alpha de récepteur de lymphocytes T humains, ladite cellule présentant une expression réduite sur la surface cellulaire du récepteur des lymphocytes T endogènes. La présente invention concerne en outre des procédés de production d'une telle cellule génétiquement modifiée, et des méthodes d'utilisation d'une telle cellule pour le traitement d'une maladie chez un sujet.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)